Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. / Li, Yi-Ping; Ramirez, Santseharay; Gottwein, Judith M; Scheel, Troels K H; Mikkelsen, Lotte; Purcell, Robert H; Bukh, Jens.

I: Proceedings of the National Academy of Sciences USA (PNAS), Bind 109, Nr. 18, 2012, s. E1101-E1110.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Li, Y-P, Ramirez, S, Gottwein, JM, Scheel, TKH, Mikkelsen, L, Purcell, RH & Bukh, J 2012, 'Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains', Proceedings of the National Academy of Sciences USA (PNAS), bind 109, nr. 18, s. E1101-E1110. https://doi.org/10.1073/pnas.1203829109

APA

Li, Y-P., Ramirez, S., Gottwein, J. M., Scheel, T. K. H., Mikkelsen, L., Purcell, R. H., & Bukh, J. (2012). Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proceedings of the National Academy of Sciences USA (PNAS), 109(18), E1101-E1110. https://doi.org/10.1073/pnas.1203829109

Vancouver

Li Y-P, Ramirez S, Gottwein JM, Scheel TKH, Mikkelsen L, Purcell RH o.a. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proceedings of the National Academy of Sciences USA (PNAS). 2012;109(18):E1101-E1110. https://doi.org/10.1073/pnas.1203829109

Author

Li, Yi-Ping ; Ramirez, Santseharay ; Gottwein, Judith M ; Scheel, Troels K H ; Mikkelsen, Lotte ; Purcell, Robert H ; Bukh, Jens. / Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. I: Proceedings of the National Academy of Sciences USA (PNAS). 2012 ; Bind 109, Nr. 18. s. E1101-E1110.

Bibtex

@article{d54e2bcd01eb42b9be39f60ff425042a,
title = "Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains",
abstract = "Hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases worldwide, but treatment options are limited. Basic HCV research required for vaccine and drug development has been hampered by inability to culture patient isolates, and to date only the JFH1 (genotype 2a) recombinant replicates spontaneously in hepatoma cells and releases infectious virus. A JFH1 chimera with the 5' end through NS2 from another genotype 2a strain, J6, had enhanced infectivity. However, the full-length J6 clone (J6CF), which we previously found to be fully functional in vivo, was replication incompetent in vitro. Through a systematic approach of culturing J6 with minimal JFH1 sequences, we identified three mutations in NS3, NS4A, and NS5B that permitted full-length J6 propagation and adaptation with infectivity titers comparable to JFH1-based systems. The most efficient recombinant, J6cc, had six adaptive mutations and did not accumulate additional changes following viral passage. We demonstrated that HCV NS3/NS4A protease-, NS5A- and NS5B polymerase-directed drugs respectively inhibited full-length J6 infection dose dependently. Importantly, the three J6-derived mutations enabled culture adaptation of the genetically divergent isolate J8 (genotype 2b), which differed from the J6 nucleotide sequence by 24{\%}. The most efficient recombinant, J8cc, had nine adaptive mutations and was genetically stable after viral passage. The availability of these robust JFH1-independent genotype 2a and 2b culture systems represents an important advance, and the approach used might permit culture development of other isolates, with implications for improved individualized treatments of HCV patients and for development of broadly efficient vaccines.",
keywords = "3' Untranslated Regions, Base Sequence, Carrier Proteins, Cell Line, DNA, Viral, Genes, Viral, Genotype, Hepacivirus, Hepatitis C, Humans, Molecular Sequence Data, Mutation, Recombination, Genetic, Viral Nonstructural Proteins, Virus Replication",
author = "Yi-Ping Li and Santseharay Ramirez and Gottwein, {Judith M} and Scheel, {Troels K H} and Lotte Mikkelsen and Purcell, {Robert H} and Jens Bukh",
year = "2012",
doi = "10.1073/pnas.1203829109",
language = "English",
volume = "109",
pages = "E1101--E1110",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "The National Academy of Sciences of the United States of America",
number = "18",

}

RIS

TY - JOUR

T1 - Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains

AU - Li, Yi-Ping

AU - Ramirez, Santseharay

AU - Gottwein, Judith M

AU - Scheel, Troels K H

AU - Mikkelsen, Lotte

AU - Purcell, Robert H

AU - Bukh, Jens

PY - 2012

Y1 - 2012

N2 - Hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases worldwide, but treatment options are limited. Basic HCV research required for vaccine and drug development has been hampered by inability to culture patient isolates, and to date only the JFH1 (genotype 2a) recombinant replicates spontaneously in hepatoma cells and releases infectious virus. A JFH1 chimera with the 5' end through NS2 from another genotype 2a strain, J6, had enhanced infectivity. However, the full-length J6 clone (J6CF), which we previously found to be fully functional in vivo, was replication incompetent in vitro. Through a systematic approach of culturing J6 with minimal JFH1 sequences, we identified three mutations in NS3, NS4A, and NS5B that permitted full-length J6 propagation and adaptation with infectivity titers comparable to JFH1-based systems. The most efficient recombinant, J6cc, had six adaptive mutations and did not accumulate additional changes following viral passage. We demonstrated that HCV NS3/NS4A protease-, NS5A- and NS5B polymerase-directed drugs respectively inhibited full-length J6 infection dose dependently. Importantly, the three J6-derived mutations enabled culture adaptation of the genetically divergent isolate J8 (genotype 2b), which differed from the J6 nucleotide sequence by 24%. The most efficient recombinant, J8cc, had nine adaptive mutations and was genetically stable after viral passage. The availability of these robust JFH1-independent genotype 2a and 2b culture systems represents an important advance, and the approach used might permit culture development of other isolates, with implications for improved individualized treatments of HCV patients and for development of broadly efficient vaccines.

AB - Hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases worldwide, but treatment options are limited. Basic HCV research required for vaccine and drug development has been hampered by inability to culture patient isolates, and to date only the JFH1 (genotype 2a) recombinant replicates spontaneously in hepatoma cells and releases infectious virus. A JFH1 chimera with the 5' end through NS2 from another genotype 2a strain, J6, had enhanced infectivity. However, the full-length J6 clone (J6CF), which we previously found to be fully functional in vivo, was replication incompetent in vitro. Through a systematic approach of culturing J6 with minimal JFH1 sequences, we identified three mutations in NS3, NS4A, and NS5B that permitted full-length J6 propagation and adaptation with infectivity titers comparable to JFH1-based systems. The most efficient recombinant, J6cc, had six adaptive mutations and did not accumulate additional changes following viral passage. We demonstrated that HCV NS3/NS4A protease-, NS5A- and NS5B polymerase-directed drugs respectively inhibited full-length J6 infection dose dependently. Importantly, the three J6-derived mutations enabled culture adaptation of the genetically divergent isolate J8 (genotype 2b), which differed from the J6 nucleotide sequence by 24%. The most efficient recombinant, J8cc, had nine adaptive mutations and was genetically stable after viral passage. The availability of these robust JFH1-independent genotype 2a and 2b culture systems represents an important advance, and the approach used might permit culture development of other isolates, with implications for improved individualized treatments of HCV patients and for development of broadly efficient vaccines.

KW - 3' Untranslated Regions

KW - Base Sequence

KW - Carrier Proteins

KW - Cell Line

KW - DNA, Viral

KW - Genes, Viral

KW - Genotype

KW - Hepacivirus

KW - Hepatitis C

KW - Humans

KW - Molecular Sequence Data

KW - Mutation

KW - Recombination, Genetic

KW - Viral Nonstructural Proteins

KW - Virus Replication

U2 - 10.1073/pnas.1203829109

DO - 10.1073/pnas.1203829109

M3 - Journal article

VL - 109

SP - E1101-E1110

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 18

ER -

ID: 44293166